HLS Therapeutics Inc. (TSE:HLS – Get Free Report)’s stock price hit a new 52-week low on Friday . The company traded as low as C$3.00 and last traded at C$3.51, with a volume of 33000 shares traded. The stock had previously closed at C$3.84.
Wall Street Analyst Weigh In
Separately, Stifel Nicolaus reduced their price target on shares of HLS Therapeutics from C$3.75 to C$3.25 in a research note on Tuesday, August 13th.
Read Our Latest Stock Report on HLS
HLS Therapeutics Trading Down 8.6 %
HLS Therapeutics (TSE:HLS – Get Free Report) last released its earnings results on Thursday, August 8th. The company reported C($0.25) EPS for the quarter, meeting the consensus estimate of C($0.25). HLS Therapeutics had a negative net margin of 40.90% and a negative return on equity of 24.82%. The business had revenue of C$19.87 million during the quarter, compared to analyst estimates of C$19.25 million. Equities analysts forecast that HLS Therapeutics Inc. will post -0.12 earnings per share for the current fiscal year.
HLS Therapeutics Company Profile
HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.
Further Reading
- Five stocks we like better than HLS Therapeutics
- How Can Investors Benefit From After-Hours Trading
- Texas Roadhouse Stock Steering for New Highs This Year
- What is the FTSE 100 index?
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Are Penny Stocks a Good Fit for Your Portfolio?
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.